Arizona State University

Sanofi Pasteur Inc.

Aventis Pasteur Limited

Virogenetics Corporation

V-core Technologies, Inc.

Scott J Goebel

Enzo Paoletti

William I Cox

James Tartaglia

Bertram L Jacobs

Steven E Pincus

Russell Robert Gettig

Jeannine P Alexander

Maurice Harmon

William Lapps

Dennis W Trent

Francois Pelloquin

Randall L Weinberg

Jim Tartaglia

The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene K1L. The poxvirus can be attenuated as to mammals, e.g., NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. The invention also provides methods for inducing an immunological response involving the poxvirus, and compositions containing the poxvirus. The antigen, epitope or immunogen that the poxvirus expresses can be at least oneantigen. Theantigen(s), epitope(s) or immunogen(s) can be SERA, ABRA, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof. Advantageously the poxvirus contains DNA coding for and expressesantigen(s) CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. Also, advantageously, the poxvirus is a NYVAC poxvirus. The invention thus also provides an anti-malarial immunogenic or immunological compositions comprising the poxvirus, and methods for inducing an immunogenic or immunological response against malaria orin a mammal comprising administering to the mammal the poxvirus or an immunological or immunogenic composition containing the poxvirus. The mammal can be a human.

Poxvirus-recombinants, compositions containing such recombinants, uses thereof, and methods of making and using the same

The invention relates to reagents and methods for enhancing an immune response using CD36 binding region/antigen hybrid polypeptides or polynucleotides encoding the hybrid polypeptides.

Enhancement of the immune response using CD36-binding domain

The present invention relates to the detection of the presence of reverse transcriptase enzymatic activity in eukaryotic cell lines. Specifically, the present invention comprises a method for discriminating between endogenous reverse transcriptase activity in a substrate cell line (e.g., avian) used as substrates for the manufacture of biological products (including viral vaccines) from exogenous infectious retrovirus by using a combination of transmissibility assay (viral replication) and PBRT assay (RT-PCR). Appropriate levels of viral amplification and number of PCR cycles are determined and employed that permit detection of exogenous infectious RT activity but not endogenous RT activity.

CoRT-PCR assay for the discrimination of endogenous reverse transcriptase activity in eukaryotic cell lines from infectious retrovirus contamination

Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector or at different loci. The second nucleic acid molecule can encode encode one translation factor or more than one translation factor. The translation factor can be a K3L open reading frame, an E3L open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an attenuated poxvirus; for instance, a NYVAC vaccinia virus or an ALVAC canarypox virus.

Vectors having enhanced expression, and methods of making and uses

Growing community of inventors

Ballston Spa, NY, United States of America

Scott J Goebel